Search Results

Featured Stories

Toggle

Showing 10 of 204 results

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab

Additional analyses examine the impact of migraine in France, Spain and the United Kingdom Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on...

Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injectio

AJOVY data highlight efficacy and safety in difficult-to-treat migraine GALA open-label extension study evaluates 7-year efficacy and safety results of COPAXONE Teva Pharmaceutical Industries Ltd....

Teva to Present New Central Nervous System Portfolio Data at 71st Annual Meeting of the American Academy

Long-term efficacy and safety data for AJOVY ® (fremanezumab-vfrm) injection for the preventive treatment of migraine are the highlight of over 20 abstracts, including four platform presentations...

Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Office’s (EPO) Opposition Division upheld patent EP 2 949 335 covering...

Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE® (glatiramer acetate injectio

Safety results from the open-label extension study of the original U.S. COPAXONE ® pivotal trial presented at the 2018 ECTRIMS Annual Meeting in Berlin Teva Pharmaceutical Industries Ltd. (NYSE and...

Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injec

Up to 7-year efficacy, safety and tolerability results from the GALA open-label extension study presented at the 70 th Annual Meeting of the AAN Over seven years, COPAXONE ® 40 mg/mL provides...

Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy

Two platform presentations and 19 posters explore the potential of fremanezumab as an investigational treatment option for the prevention of migraine COPAXONE ® (glatiramer acetate injection) and...

Teva Reports 2017 Full Year and Fourth Quarter Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today reported results for the year and the quarter ended December 31, 2017.     FY 2017 Q4 2017 Revenues $22.4 billion $5.5 billion Cash flow from...

New Survey Highlights Misconceptions about Family Planning among Women with Relapsing Forms of Multiple S

88% of women with RMS were concerned they would not be able to have children, despite studies that show otherwise More, and better, information on family planning options is needed Teva...

Teva Completes Amendment to Credit Facilities

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced amendments to its USD and JPY term loan and revolving credit facilities, providing the company greater flexibility in its...